Iressa gefitinib: Phase III data

In an open-label, Japanese Phase III trial in 172 chemotherapy-naïve patients with EGFR mutations, 250 mg oral Iressa once daily met the primary endpoint of significantly increasing PFS vs. cisplatin ...